Combining Scancell's melanoma drug iSCIB1+ with Yervoy and Opdivo significantly improved patient overall response rate.

Arch Biopartners has initiated subject recruitment in its Phase II study aimed at assessing cilastatin in preventing AKI.

Diakonos Oncology has dosed the first subject in its Phase II trial of DOC1021 for treating glioblastoma (GBM).

Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

The first patient has been treated with InterVene’s Recana thrombectomy system for restoring patency (blood flow) in chronically obstructed deep veins and venous stents.

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), succeeding in a Phase IIb trial but failing in a Phase III study.

New guidelines recommended by WHO will need to be backed with funding to be implemented at scale in affected communities.

Walgreens is not the only company in the US that has tried to expand beyond standard pharmacy operations. For example, CVS had tried to assist with clinical trials but closed the facility down after ...

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.